Article
Washington, DC-The FDA is revising its rules for safe drug manufacturing to direct more attention and resources to the aspects of manufacturing that pose the greatest risk to public health. It is the first time in 25 years the FDA is amending its rules.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.